RIGEL PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Mar 5, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 5, 2024

RIGL$42.05+6.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(In thousands, except share and per share amounts)


· · As of December 31, ·
· · 2023 · 2022 ·
Assets
Current assets:
Cash and cash equivalents	$32,786	$24,459
Short-term investments	24,147	33,747
Accounts receivable, net	30,550	40,320
Inventories	5,522	9,118
Prepaid and other current assets	6,261	8,259
Total current assets	99,266	115,903
Property and equipment, net	165	857
Intangible asset, net	13,878	14,949
Operating lease right-of-use assets	861	1,930
Other assets	3,055	640
Total assets	$117,225	$134,279
Liabilities and stockholders’ deficit
Current liabilities:
Accounts payable	$7,142	$22,508
Accrued compensation	8,676	8,866
Accrued research and development	3,513	7,708
Revenue reserves and refund liability	15,684	12,145
Other accrued liabilities	5,334	6,485
Lease liabilities, current portion	692	1,133
Deferred revenue	1,355	1,369
Loans payable, net, current portion	7,229	—
Other long-term liabilities, current portion	3,642	4,997
Total current liabilities	53,267	65,211
Long-term portion of lease liabilities	285	972
Long-term portion of loans payable, net	52,373	39,448
Other long-term liabilities	39,944	42,264
Total liabilities	145,869	147,895

Commitments

Stockholders’ deficit:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; none issued and outstanding as of December 31, 2023 and 2022	—	—
Common stock, $0.001 par value; 400,000,000 shares authorized; 174,825,610 and 173,398,645 shares issued and outstanding as of December 31, 2023 and 2022, respectively	175	174
Additional paid-in capital	1,378,723	1,368,822
Accumulated other comprehensive income (loss)	8	(153)
Accumulated deficit	(1,407,550)	(1,382,459)
Total stockholders’ deficit	(28,644)	(13,616)
Total liabilities and stockholders’ deficit	$117,225	$134,279

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.